EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

12-month clinical trial of bioencapsulated terbinafine yielded inconsistent resolution for the treatment of Emydomyces testavorans in the Blanding’s turtle (Emydoidea blandingii)

David J Minich iD, Anthony J Cerreta iD, Alexis Nix, Daniel Thompson, Lilyvette Barajas, Ashley Portala, Dania Gamez, Allison Sacerdote-Velat, Matthew R O'Connor, Jennifer M Reinhart iD, Sherry Cox iD, Laura Adamovicz und 2 weitere

American Journal of Veterinary Research · 01.11.2026 · 87 (11)

DOI: 10.2460/ajvr.26.06.0242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Veterinary Research, erschienen am 01.11.2026. Verfasst von David J Minich und 13 weiteren Autor:innen. Beteiligte Einrichtung: Illinois Zoological and Aquatic Animal Residency, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL. Hauptthemen laut MEDLINE: Terbinafine, Antifungal Agents, Turtles. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Evaluate multidose bioencapsulated terbinafine for the treatment of Emydomyces testavorans in naturally infected Blanding’s turtles ( Emydoidea blandingii ) and determine if this protocol resulted in therapeutic drug concentrations.

Methods

Blanding’s turtles housed within a quarantine facility were treated with oral terbinafine (30 mg/kg) bioencapsulated within earthworms delivered every 48 hours for 12 months in this experimental study. For all turtles, plasma terbinafine concentrations were quantified, and turtles were routinely tested for of E testavorans through quantitative PCR of combined oral, cloacal, and carapace/plastron swabs.

Results

13 Blanding’s turtles were enrolled, and no turtle consistently tested negative via quantitative PCR for E testavorans after 12 months of treatment. The median plasma terbinafine concentrations at months 3 and 6 (trough concentrations) were 18 ng/mL (11 to 78 ng/mL) and 36 ng/mL (10 to 76 ng/mL), respectively. The median plasma terbinafine concentrations at months 9 and 12 (peak concentrations) were 163 ng/mL (61 to 575 ng/mL) and 100 ng/mL (13 to 247 ng/mL), respectively. Plasma terbinafine concentrations inconsistently measured above the MIC for E testavorans . No correlation was observed between plasma terbinafine concentrations and E testavorans target copy number by quantitative PCR.

Conclusions

Multdose treatment at 30 mg/kg with orally administered, bioencapsulated terbinafine every 48 hours for 12 months failed to achieve molecular resolution of natural E testavorans infection in Blanding’s turtles and failed to consistently achieve appropriate plasma concentrations. Clinical Relevance Emydomyces testavorans is associated with a challenging disease process and is of increasing concern for the health, welfare, and conservation of chelonian species. Further investigation of alternative dosing regimens and/or the use of oral terbinafine as part of multimodal treatment protocols is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TerbinafineAntifungal AgentsTurtlesAnimalsAdministration, OralNaphthalenesFemale

Stichwörter der Autor:innen

Emydoidea blandingiiEmydomyces testavoransbioencapsulationclinical trialterbinafine

Substanzen

TerbinafineAntifungal AgentsNaphthalenes

Autor:innen und Institutionen

  • Illinois Zoological and Aquatic Animal Residency, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL.
  • Watson Armour III Center for Animal Health and Welfare, Shedd Aquarium, Chicago, IL.
  • Forest Preserve District of DuPage County, Wheaton, IL.
  • Chicago Academy of Sciences, Chicago, IL.
  • Georgia Aquarium, Atlanta, GA.
  • College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL.

ORCID-Profile: David J Minich, Anthony J Cerreta, Jennifer M Reinhart, Sherry Cox

Zitieren

APA

Minich, D. J., Cerreta, A. J., Nix, A., Thompson, D., Barajas, L., Portala, A., Gamez, D., Sacerdote-Velat, A., O'Connor, M. R., Reinhart, J. M., Cox, S., Adamovicz, L., Tang, K. N., & Allender, M. C. (2026). 12-month clinical trial of bioencapsulated terbinafine yielded inconsistent resolution for the treatment of Emydomyces testavorans in the Blanding’s turtle (Emydoidea blandingii). American Journal of Veterinary Research, 87(11). https://doi.org/10.2460/ajvr.26.06.0242

Vancouver

Minich DJ, Cerreta AJ, Nix A, Thompson D, Barajas L, Portala A, et al. 12-month clinical trial of bioencapsulated terbinafine yielded inconsistent resolution for the treatment of Emydomyces testavorans in the Blanding’s turtle (Emydoidea blandingii). American Journal of Veterinary Research. 2026;87(11). doi:10.2460/ajvr.26.06.0242

BibTeX
@article{Minich2026,
  author = {Minich, David J and Cerreta, Anthony J and Nix, Alexis and Thompson, Daniel and Barajas, Lilyvette and Portala, Ashley and Gamez, Dania and Sacerdote-Velat, Allison and O'Connor, Matthew R and Reinhart, Jennifer M and Cox, Sherry and Adamovicz, Laura and Tang, Karisa N and Allender, Matthew C},
  title = {12-month clinical trial of bioencapsulated terbinafine yielded inconsistent resolution for the treatment of Emydomyces testavorans in the Blanding’s turtle (Emydoidea blandingii)},
  journal = {American Journal of Veterinary Research},
  year = {2026},
  volume = {87},
  number = {11},
  doi = {10.2460/ajvr.26.06.0242}
}
Kostenlos starten →